title: Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil--early experience.
abstract: BACKGROUND
  Malignant atrophic papulosis (Köhlmeier-Degos disease; MAP) is an uncommon endotheliopathy with pathological findings similar to the vascular lesions of systemic sclerosis. These two disorders can overlap. When associated with visceral lesions, MAP has been considered almost universally and rapidly fatal. A recent report described dramatic response to treatment with eculizumab, but disease progression after initial response to therapy has occurred.
  
  
  METHODS
  We describe the clinical and pathologic findings in two patients, one with MAP and the other with MAP like lesions, who received treatment with subcutaneous treprostinil. One patient had an overlap syndrome with features of systemic lupus erythematosus (SLE) and scleroderma and severe pulmonary hypertension. She also had very extensive MAP like cutaneous lesions. There was no evidence of central nervous system (CNS) disease and laparoscopy revealed no visible MAP lesions on the serosa of the small bowel. The second patient had experienced life-threatening disease progression despite ongoing eculizumab therapy. During this treatment, he had developed CNS and bladder involvement with neurologic symptoms and gross hematuria.
  
  
  RESULTS
  Patient one was placed on therapy with treprostinil for her pulmonary hypertension, but in the months subsequent to initiation of treatment, dramatic and complete resolution of cutaneous MAP like lesions and disabling digital pain occurred. In patient two, therapy with treprostinil was temporally associated with clearing of hematuria, resolution of CNS symptoms and improvement in MRI findings.
  
  
  CONCLUSIONS
  Treprostinil may offer a second effective treatment approach to individuals with MAP or "rescue therapy" to those in whom eculizumab treatment has failed to maintain suppression of disease activity.
authors.affiliation: Steffens Scleroderma Center, Saratoga Springs, NY, USA. leeshapiromd@gmail.com
authors.forename: Lee S
authors.initials: LS
authors.lastname: Shapiro
authors.forename: Aixa E
authors.initials: AE
authors.lastname: Toledo-Garcia
authors.forename: Jessica F
authors.initials: JF
authors.lastname: Farrell
mesh_terms: D000293:Adolescent; D000328:Adult; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008297:Male; D054853:Malignant Atrophic Papulosis / Q000150:complications / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000150:complications
chemical_list: D011464:Epoprostenol; C427248:treprostinil
references.citation: Clin Exp Dermatol. 2007 Sep;32(5):483-7
references.pmid: 17692056
references.citation: Arch Dermatol. 1969 Nov;100(5):575-81
references.pmid: 5350410
references.citation: Am J Ophthalmol. 1968 Feb;65(2):164-9
references.pmid: 5636016
references.citation: Semin Dermatol. 1995 Jun;14(2):99-105
references.pmid: 7640203
references.citation: J Am Acad Dermatol. 1997 Feb;36(2 Pt 2):317-9
references.pmid: 9039209
references.citation: Am J Clin Pathol. 2011 Apr;135(4):599-610
references.pmid: 21411783
references.citation: Orphanet J Rare Dis. 2013 Jan 14;8:10
references.pmid: 23316694
references.citation: Angiogenesis. 2011 Mar;14(1):17-27
references.pmid: 21049284
references.citation: Dermatologica. 1987;175(1):45-6
references.pmid: 3609417